Pfizer Wins RAPAMUNE Patent Case Against Watson
Posted on January 31, 2013 at 08:02 AM EST
Pfizer Inc. (NYSE: PFE ) said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed. The company brought a patent infringement action in April